Matthew Hewitt, the head of clinical development at Lonza’s Walkersville headquarters, unveiled the company’s Cocoon platform at the BPI Theater @ BIO on Tuesday, 4 June 2019. Scalable, fully closed, single-use–capable, and intuitively interfaced, the platform offers what Hewitt terms a kaleidoscope approach to cell therapy manufacturing because it enables drug developers increased ability to customize their processes. The technology also addresses many pain points specific to the cost of cleanroom space, labor, and scalability. These exciting features, Hewitt concludes, have compelled Lonza to put the system on the fast track to the clinic.